Synaptogenix Inc (SNPX)

[Antti]

Exactly. There are always variability between patients and also between measurements.

There's no way to refute the great results they got in previous trial. P value and effect size for the (predefined) memantine free patient population were great.

This makes it quite/very probable that we are going to see similar results in the ongoing trial. As we are getting closer and closer to enrollment completion I suspect more people are starting to pay attention to the company. I think that risk/reward ratio is so huge here that the company is bound to get a lot more interest in coming months.

I estimate that there are around 80 patients currently enrolled to the study and the enrollment will be completed around mid February.